Canaccord Genuity analyst Matt Bottomley maintained a Hold rating on Canopy Growth (CGC) today and set a price target of C$28.00. The company’s shares closed last Monday at $22.13.
According to TipRanks.com, Bottomley is a 3-star analyst with an average return of 2.1% and a 43.1% success rate. Bottomley covers the Healthcare sector, focusing on stocks such as Harvest Health & Recreation, iAnthus Capital Holdings, and Curaleaf Holdings.
Currently, the analyst consensus on Canopy Growth is a Moderate Buy with an average price target of $24.07, representing a 3.9% upside. In a report issued on February 14, PI Financial also downgraded the stock to Hold with a C$30.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.74 and a one-year low of $13.81. Currently, Canopy Growth has an average volume of 8.9M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite.
Read More on CGC:
